文献速递头痛与眩晕

早期使用依瑞奈珠单抗与非特异性口服偏头痛预防药对比:APPRAISE随机临床试验

Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2024-01-01

APPRAISE试验为12个月开放标签、多中心、活性对照、4期随机临床试验,在17个国家84个中心纳入621例既往1或2种预防治疗失败的发作性偏头痛成人患者,按2:1随机接受依瑞奈珠单抗或非特异性口服偏头痛预防药。第12个月时,依瑞奈珠单抗组达到主要终点(完成1年初始治疗且月偏头痛天数较基线减少≥50%)的比例显著高于口服预防药组(56.2% vs 16.8%;OR 6.48;95%CI 4.28-9.82;P<.001)。

要点

  • 第12个月主要终点达标率依瑞奈珠单抗组56.2% vs 口服预防药组16.8%(OR 6.48;95%CI 4.28-9.82;P<.001)。
  • PGIC≥5应答率依瑞奈珠单抗组76.0% vs 口服预防药组18.8%(OR 13.75;95%CI 9.08-20.83;P<.001)。
  • 因不良事件停药依瑞奈珠单抗组2.9%(12/408)vs 口服预防药组23.3%(48/206),未发现新安全信号。

核心结论

  • 在既往1或2种预防治疗失败的发作性偏头痛患者中,早期使用依瑞奈珠单抗较持续使用非特异性口服偏头痛预防药提供更大且持续的疗效、安全性和依从性。

研究设计与样本

  • 12个月开放标签、多中心、活性对照、4期随机临床试验(APPRAISE),2019年5月15日至2021年10月1日在17个国家84个中心开展。
  • 纳入18岁及以上、偏头痛病史12个月或更长、每月偏头痛天数4天及以上但少于15天的患者。
  • 621例随机患者(平均[SD]年龄41.3[11.2]岁;545例女性[87.8%];依瑞奈珠单抗组413例[66.5%];口服预防药组208例[33.5%]),按2:1随机接受依瑞奈珠单抗或非特异性口服偏头痛预防药,允许按标签调整剂量。

主要发现

  • 第12个月达到主要终点(完成1年初始治疗且月偏头痛天数较基线减少≥50%)的患者:依瑞奈珠单抗组232/413(56.2%)vs 口服预防药组35/208(16.8%);OR 6.48;95%CI 4.28-9.82;P<.001。
  • 第12个月PGIC量表≥5的应答率:依瑞奈珠单抗组314/413(76.0%)vs 口服预防药组39/208(18.8%);OR 13.75;95%CI 9.08-20.83;P<.001。
  • 治疗期间月偏头痛天数累积平均变化:依瑞奈珠单抗组-4.32 vs 口服预防药组-2.65;治疗差异[SE]:-1.67[0.35]天;P<.001。
  • 换药患者:依瑞奈珠单抗组9/413(2.2%)vs 口服预防药组72/208(34.6%)。
  • 因不良事件停药:依瑞奈珠单抗组12/408(2.9%)vs 口服预防药组48/206(23.3%);未发现新安全信号。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with migraine often cycle through multiple nonspecific preventive medications due to poor tolerability and/or inadequate efficacy leading to low adherence and increased disease burden. OBJECTIVE: To compare the efficacy, tolerability, patient adherence, and patient satisfaction between erenumab and nonspecific oral migraine preventive medications (OMPMs) in patients with episodic migraine (EM) who had previously failed 1 or 2 preventive treatments. DESIGN, SETTING, AND PARTICIPANTS: The 12-month prospective, interventional, global, multicenter, active-controlled, randomized clinical trial comparing sustained benefit of 2 treatment paradigms (erenumab qm vs oral prophylactics) in adult episodic migraine patients (APPRAISE) trial was a 12-month open-label, multicenter, active-controlled, phase 4 randomized clinical trial conducted from May 15, 2019, to October 1, 2021. This pragmatic trial was conducted at 84 centers across 17 countries. Overall, participants 18 years or older with a 12-month or longer history of migraine, and 4 or more but fewer than 15 monthly migraine days (MMDs) were included. INTERVENTIONS: Patients were randomized (2:1) to receive erenumab or OMPMs. Dose adjustment was permitted (label dependent). MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of patients completing 1 year of the initially assigned treatment and achieving a reduction of 50% or greater from baseline in MMDs at month 12. Secondary end points included the cumulative mean change from baseline in MMDs during the treatment period and the proportion of responders according to the Patients' Global Impression of Change (PGIC) scale at month 12 for patients taking the initially assigned treatment. RESULTS: A total of 866 patients were screened, of whom 245 failed the screening and 621 completed the screening and baseline period. Of the 621 randomized patients (mean [SD] age, 41.3 [11.2] years; 545 female [87.8%]; 413 [66.5%] in the erenumab group; 208 [33.5%] in the OMPM group), 523 (84.2%) completed the treatment phase, and 98 (15.8%) discontinued the study. At month 12, significantly more patients assigned to erenumab vs OMPM achieved the primary end point (232 of 413 [56.2%] vs 35 of 208 [16.8%]; odds ratio [OR], 6.48; 95% CI, 4.28-9.82; P <.001). Compared with OMPMs, treatment with erenumab showed higher responder rate (314 of 413 [76.0%] vs 39 of 208 [18.8%]; OR, 13.75; 95% CI, 9.08-20.83; P <.001) on the PGIC scale (≥5 at month 12). Significant reduction in cumulative average MMDs was reported with erenumab treatment vs OMPM treatment (-4.32 vs -2.65; treatment difference [SE]: -1.67 [0.35] days; P < .001). Substantially fewer patients in the erenumab arm compared with the OMPM arm switched medication (9 of 413 [2.2%] vs 72 of 208 [34.6%]) and discontinued treatment due to adverse events (12 of 408 [2.9%] vs 48 of 206 [23.3%]). No new safety signals were identified. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial demonstrated that earlier use of erenumab in patients with EM who failed 1 or 2 previous preventive treatments provided greater and sustained efficacy, safety, and adherence than continuous OMPM. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03927144.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Pozo-Rosich P, Dolezil D, Paemeleire K, et al. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial. JAMA Neurol. 2024. PMID: 38526461. doi:10.1001/jamaneurol.2024.0368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。